KIF5B-RET is reported in a low percentage of lung cancers and is more frequent in non-smokers, in patients with adenocarcinoma, and exists exclusively with other mutations, such as EGFR, Kras, Braf, ErbB2 or EML4/ALK fusions[8,12,13]. Here, ALK is linked to lung carcinoma.